Recent News

• 09.12.2025 - Mayank Mamtani
• 09.09.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
• 08.25.2025 - Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
• 08.12.2025 - Theravance Biopharma Second Quarter 2025 Earnings Results Call
• 08.12.2025 - Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 07.28.2025 - Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
• 07.23.2025 - Theravance Biopharma to Participate in an Upcoming Investor Conference

Recent Filings

• 08.25.2025 - EX-99.1 EX-99.1
• 08.25.2025 - 8-K Current report
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.20.2025 - 8-K Current report
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - 8-K Current report